Skip header and navigation

1 records – page 1 of 1.

Effectiveness of the targeted hepatitis B vaccination program in Greenland.
Am J Public Health. 2012 Feb;102(2):277-84
Publication Type
Malene L Børresen
Anders Koch
Robert J Biggar
Karin Ladefoged
Mads Melbye
Jan Wohlfahrt
Tyra Grove Krause
Author Affiliation
Department of Epidemiology Research, Statens Serum Institut (SSI), Copenhagen, Denmark.
Am J Public Health. 2012 Feb;102(2):277-84
Publication Type
Greenland - epidemiology
Hepatitis B - prevention & control - transmission
Hepatitis B Antibodies - blood
Hepatitis B Surface Antigens - blood
Hepatitis B Vaccines - administration & dosage - immunology
Immunization Programs - statistics & numerical data
Infant, Newborn
Infectious Disease Transmission, Vertical - prevention & control
Pregnancy Complications, Infectious - immunology
Program Evaluation - statistics & numerical data
Retrospective Studies
Risk factors
To evaluate the effectiveness of the hepatitis B virus (HBV) vaccination program in Greenland, which targets children born to mothers who are positive for HBV surface antigen (HBsAg), we determined vaccination coverage, levels of postvaccination antibodies, and frequency of breakthrough infections in at-risk children.
We conducted a population-based retrospective cohort study with data from nationwide registries. We identified all children born to HBsAg-positive mothers from 1992 to 2007 and collected data on their HBV vaccination status. In 2008 to 2010, we tested the children for HBV core antibody, HBsAg, and anti-HBsAg antibody (HBsAb).
Of 4050 pregnant women, 3.2% were HBsAg positive. Of 207 children born to these women, 20% received no vaccinations, and only 58% received at least 3 vaccinations. At follow-up, HBsAb levels in vaccinated children were much lower than expected, and 8 (6%) of 140 at-risk children had breakthrough infections, with 4 chronically infected (persistently HBsAg positive).
The prevention program targeting children at risk for HBV in Greenland is ineffective. HBV vaccination should be included in the universal childhood vaccination program, and postvaccination HBsAb levels should be monitored.
Cites: CMAJ. 2009 Jan 20;180(2):196-20219153395
Cites: Hepatology. 1999 Mar;29(3):954-910051503
Cites: J Infect Dis. 2009 Jul 1;200(1):39-4719469708
Cites: Expert Rev Vaccines. 2009 Jul;8(7):907-2019538116
Cites: J Infect Dis. 2009 Nov 1;200(9):1390-619785526
Cites: Am J Epidemiol. 1974 Jan;99(1):50-74204315
Cites: Bull World Health Organ. 2004 Feb;82(2):99-10515042231
Cites: J Viral Hepat. 2010 Mar;17(3):162-7019780937
Cites: Am J Epidemiol. 1977 Feb;105(2):99-106835567
Cites: Am J Epidemiol. 1978 Aug;108(2):121-5707473
Cites: Int J Technol Assess Health Care. 1991;7(3):256-621834601
Cites: Lancet. 1992 May 23;339(8804):12871349679
Cites: Pediatrics. 1992 Jul;90(1 Pt 2):170-31534885
Cites: JAMA. 1993 Dec 22-29;270(24):2931-48254852
Cites: J Viral Hepat. 1997 Sep;4(5):339-499310933
Cites: N Engl J Med. 1997 Dec 11;337(24):1733-459392700
Cites: Ann Intern Med. 2005 Mar 1;142(5):333-4115738452
Cites: Pediatr Infect Dis J. 2005 Sep;24(9):786-9216148845
Cites: J Med Virol. 2006 Feb;78(2):169-7716372285
Cites: BMJ. 2006 Feb 11;332(7537):328-3616443611
Cites: J Epidemiol Community Health. 2007 Jul;61(7):578-8417568048
Cites: Pediatrics. 2007 Aug;120(2):e373-8117636112
Cites: J Infect Dis. 2007 Nov 15;196(10):1487-9218008228
Cites: Scand J Gastroenterol. 2008 Mar;43(3):334-4318266176
Cites: Vaccine. 2008 Nov 18;26(49):6266-7318848855
Cites: Lancet. 2000 Jul 22;356(9226):337-811071210
Cites: Vaccine. 2000 Nov 22;19(7-8):877-8511115711
Cites: Clin Exp Allergy. 2002 Mar;32(3):367-7211940065
Cites: Lancet. 2002 Aug 31;360(9334):691-212241878
Cites: BMJ. 2003 Jan 11;326(7380):10512521983
Cites: Vaccine. 2003 Apr 2;21(15):1704-912639493
Cites: Int J Cancer. 2003 Dec 20;107(6):1017-2214601064
Cites: Antiviral Res. 2003 Oct;60(2):75-814638401
Cites: Liver Int. 2009 Jan;29 Suppl 1:133-919207977
PubMed ID
21940914 View in PubMed
Less detail